Because cytokine and chemokine levels are relevant in the context of ARDS patients with COVID-19, serum levels of CXCL9 and CXCL10 during the acute phase were compared to both chemokines’ levels during recovery phases (4 months post-infection). This evidence concerns the gene CXCL9 and COVID-19.